Journal
GENETICS IN MEDICINE
Volume 17, Issue 9, Pages 733-738Publisher
SPRINGERNATURE
DOI: 10.1038/gim.2014.181
Keywords
biomarkers; Food and Drug Administration; genetic testing; personalized medicine; pharmacogenetics
Categories
Funding
- program Equipe Espoir de la Recherche, Fondation pour la Recherche Medicale, Paris, France [DEQ20101221475]
Ask authors/readers for more resources
Purpose: The aim of this study was to compare guidance for genetic testing in US Food and Drug Administration (FDA)-approved drug labels in oncology to those of drugs for other therapeutic areas. Methods: We reviewed labels of all the FDA-approved drugs with labels containing pharmacogenomic information. We assessed whether genetic testing was required or recommended before prescription and, if not, the reason for pharmacogenomic labeling. Results: We included 140 drugs corresponding to 158 drug-biomarker pairs. Overall, 46 (29%) of 158 pairs stated a requirement or recommendation for genetic biomarker testing in the label. This proportion was higher in oncology than in other areas (62 vs. 12%; P < 0.001). For the 112 drug-biomarker pairs (including 20 in oncology) without recommendation or requirement for genetic testing, the main reasons for pharmacogenomic labeling were change in pharmacologic end points (32%) and higher risk of toxicity (30%). For 11 (10%) pairs (including 1 in oncology), a genetic biomarker was mentioned only to inform that it was not relevant. In oncology, the main reasons for pharmacogenomic labeling were higher risk of toxicity (55%) and definition of the mechanism of action (25%). Conclusion: Inclusion of biomarkers in drug labels does not always correspond to required or recommended genetic testing, especially outside oncology. Genet Med advance
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available